Indapamide/levamlodipine/valsartan - Ahn-Gook Pharmaceuticals
Alternative Names: AGSAVI; S-amlodipine/valsartan/indapamide - Ahn-Gook PharmaceuticalsLatest Information Update: 19 May 2023
At a glance
- Originator Ahn-Gook Pharmaceutical
- Class Antihypertensives; Branched-chain amino acids; Cardiovascular therapies; Dihydropyridines; Indoles; Nicotinic acids; Small molecules; Sulfonamides; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Thiazide-like diuretics
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Hypertension
Most Recent Events
- 19 May 2023 Chemical structure information added
- 24 Aug 2022 Clinical trials in Hypertension in South Korea (PO)
- 18 Aug 2022 Ahn-Gook Pharmaceuticals and Daehwa Pharmaceutical plans a phase III trial for Hypertension (Treatment-experiemced) in September 2022 (NCT05503953)